12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cimzia certolizumab pegol: Phase III data

Top-line data from the double-blind, international Phase III RAPID-PsA trial in 409 patients with adult-onset active and progressive psoriatic arthritis showed that Cimzia significantly improved signs and symptoms of psoriatic arthritis from baseline to week 12 vs. placebo. Details were not disclosed. Patients received placebo, 200 mg Cimzia every 2 weeks or 400 mg Cimzia every 4...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >